New drug cocktail aims to shrink liver tumors for surgery
NCT ID NCT07515963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a chemotherapy regimen called FULIRI, combined with either bevacizumab or cetuximab, as a first treatment for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors enough so they can be surgically removed. The study will enroll 24 adults aged 18-75 who have not had prior treatment for their liver metastases. Researchers will measure how many patients' tumors shrink significantly and how many can then have successful surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FULIRI chemotherapy (irinotecan liposome, leucovorin, 5-FU) plus bevacizumab or cetuximab
- What this could lead to
- If successful, this could help shrink liver tumors enough to allow surgical removal, potentially improving long-term survival in colorectal cancer patients.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply broadly. Chemotherapy and targeted drugs have significant side effects, and not all patients will respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a registry make endoscopic procedures safer and more effective?
- A new clue in the fight against colorectal cancer recurrence?
- One simple score to rate colorectal cancer surgery quality?
- Engineered virus joins forces with immunotherapy to fight resistant cancers
- Massive 30-Year Women's health study reveals hidden disease links